Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.24 EUR
Change Today -0.008 / -3.25%
Volume 0.0
As of 2:08 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (B1N) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - €0.44
52 Week Low
08/26/15 - €0.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIONOMICS LTD (B1N)

Related News

No related news articles were found.

bionomics ltd (B1N) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (B1N) Details

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company’s product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials and Phase I multiple ascending dose trials for the treatment of generalized anxiety disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers's disease; BNC101, a monoclonal antibody, which has completed preclinical studies that targets cancer stem cells; and BNC105, a novel compound to disrupt the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has collaboration agreement with Merck & Co. to develop compounds targeting cognitive impairment in conditions, such as ADHD, alzheimer’s disease, parkinson’s disease, and schizophrenia. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (B1N) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$483.8K
Chief Financial Officer
Total Annual Compensation: A$165.7K
Chief Medical Officer
Total Annual Compensation: A$433.5K
Legal Counsel and Company Secretary
Total Annual Compensation: A$45.8K
Chief Scientific Officer
Total Annual Compensation: A$47.2K
Compensation as of Fiscal Year 2015.

bionomics ltd (B1N) Key Developments

Bionomics Ltd. Reports Audited Group Earnings Results for the Year Ended June 30, 2015

Bionomics Ltd. reported audited group earnings results for the year ended June 30, 2015. For the period, the company's net operating and investing cash outflows for the period increased by 137% to AUD 4,639,331, revenue from ordinary activities decreased by 65% to AUD 6,827,277, revenue and other income decreased by 40% to AUD 16,616,405, compared with AUD 27,545,996 for the period to 30 June 2014 and loss from ordinary activities after tax attributable to members decreased by 629% to AUD 16,949,405. The current year loss reflects the Company's investment in research and development activities. The operating loss after tax of the Group for the period was AUD 16,949,405 and reflects the Company's continued execution of its business plan.

Bionomics Limited Appoints Tony Colasin as Chief Business Officer

Bionomics Limited announced the appointment of Tony Colasin as Chief Business Officer. Based in San Diego, California, Mr. Colasin will lead corporate development including business development and strategic opportunities. He joins Bionomics from Ironwood Pharmaceuticals, where he served as Vice President of Corporate Development and was responsible for strategy and tactical oversight of in-licensing, and mergers and acquisitions.

Bionomics Files Patent for Use of BNC105 in Combination with PD-1 and CTLA-4 Immuno-Oncology Antibodies

Bionomics Limited announced that it filed a patent application covering the use of BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer. This new patent is based on important preclinical findings regarding the synergistic effects in preclinical models of a combination of the company's proprietary novel oncology compound BNC105 and antibodies against known immuno-oncology targets. In these preclinical studies animals with MC38 colorectal tumours had 40% inhibition of tumour growth when treated with BNC105 as a monotherapy and 74% inhibition in tumour growth when treated with an antibody targeting PD1. Animals treated with the combination of BNC105 + anti-PD1 therapy experienced greater benefit with 97% inhibition in tumour growth. In addition animals with CT26 colorectal tumours had 27% inhibition of tumour growth when treated with BNC105 as a monotherapy and 14% inhibition in tumour growth when treated with an antibody targeting CTLA4. Animals treated with the combination of BNC105 + anti-CTLA4 therapy experienced greater benefit with 70% inhibition in tumour growth. Bionomics aims to present these data at the Molecular Targets and Cancer Therapeutics conference in November this year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B1N:GR €0.24 EUR -0.008

B1N Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B1N.
View Industry Companies

Industry Analysis


Industry Average

Valuation B1N Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at